Sponsored

The OncLive® Sponsored section encompasses all sponsored content that is presented as articles, video interviews, webinars, blog posts, and more across various types of malignancies, including breast cancer, lung cancer, hematologic cancers, gynecologic cancers, gastrointestinal cancers, genitourinary cancers, and more.

Newly approved therapy for polycythemia vera enables physicians to focus on treating the totality of this debilitating rare blood cancer earlier in the journey

November 30th 2021

Looking Deeper Inside Myelofibrosis

November 18th 2021

A New Frontier in Cholangiocarcinoma Management and Treatment

November 18th 2021

This content was developed in collaboration with Servier Pharmaceuticals and Onc Live

How Advancing the Science of Bladder Cancer Aims to Transform Patients’ Lives

November 4th 2021

Minimal Residual Disease Testing for Patients with Chronic Lymphocytic Leukemia

August 25th 2021

Adaptive Biotechnologies OncLive Sponsored Content Q&A

Providing the Diagnostics You Need in Breast Cancer Care with One Lab

August 23rd 2021

Dr. Robert L. Coleman discusses Rubraca® (rucaparib) for 2L Maintenance Treatment

August 18th 2021

Our Path Forward in Leading a Revolution in Cancer Care

August 11th 2021

Chatrick Paul of AstraZeneca shares his perspective on the mission to eradicate cancer as a leading cause of death

Discovering New Medicines in Cancer

July 15th 2021

Our ambition is to outsmart cancer by translating our science into health. The combination of our people and heritage is a particular advantage we have in achieving this goal. Our teams are curious, bold, and driven to deliver potentially transformative medicines to patients with cancer. Our heritage of science-based precision medicine and immuno-oncology means that we can branch into synergies to bridge different aspects of cancer research, in an agile and uncompromising manner. Our research focus is on three key mechanistic pillars: oncogenic pathways; immuno-oncology (IO); and DNA damage response (DDR); and, we are developing new approaches in key tumor types in GI, GU and thoracic cancers, all areas with significant unmet treatment needs. Together, we are transforming cancer care—today and tomorrow.

Best Practices in the Evolving and Complex Lung Cancer Testing Journey

June 30th 2021

ERLEADA® (apalutamide) Continued to Demonstrate Significant Improvement in Overall Survival for Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Analysis of the TITAN Study

June 14th 2021

Next-Generation Sequencing Minimal Residual Disease Testing in Blood Cancer Is Needed Now More Than Ever

June 9th 2021

Sponsored Content by Adaptive Biotechnologies

A Conversation about Somatic, Incidental Germline, and Standalone Germline Testing in Clinical Practice

June 7th 2021

Sponsored Content by Tempus

Advancing Care in Metastatic Breast Cancer

June 3rd 2021

Sponsored Content by SANOFI

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Offers Subcutaneous CD38-Directed Antibody to Health Care Providers and Their Multiple Myeloma Patients

April 26th 2021

Since the U.S. Food and Drug Administration (FDA) approval of DARZALEX® (daratumumab) in 2015, the first CD38-directed antibody to treat multiple myeloma has been used in the treatment of more than 68,000 patients in the U.S. alone.

Multi-stakeholder collaboration: the catalyst for innovation in kidney cancer care

March 31st 2021

Sponsored Content by Ipsen

Applying RxPONDER to Clinical Practice

March 30th 2021

Faculty from the Miami Breast Cancer Conference® discuss how to apply the RxPONDER data to clinical practice.

More Can Be Done for Asian American Lung Cancer Patients

December 22nd 2020

Targeted Treatment Helps Delay ALK+ mNSCLC Progression

December 16th 2020

Remarkable progress has been made in the treatment of ALK+ mNSCLC patients, and the field continues to grow at a rapid pace.

Rethinking How We Approach Stage 3 Lung Cancer Treatment

October 20th 2020

As ongoing research continues to unlock the mechanisms of non–small cell lung cancer, it’s becoming increasingly clear that healthcare providers need to start rethinking how treatment is approached—especially for Stage 3 disease.